News
January 2019: Chaotic Brexit situation will also have consequences for release of (bio)pharmaceuticals and time to market
Read more
November 2018. Article “Bioanalytical Strategy: Authorities’ expectations to consider” published from VelaLabs’ CEO, Dr. Markus Fido
Read more
September 2018. VelaLabs is now registered at the FDA.
Read more
September 2018. VelaLabs is now a listed CRO of MSD.
Read more
August 2018. VelaLabs expertise covers a variety of biomolecules and is now presenting some basic information for more than 20 blockbuster drugs in fact sheets.
Read more
During summer 2018, VelaLabs has further expanded analytical capabilities for excipients in biopharmaceutical formulations.
Read more
In March 2018, the leadership of VelaLabs in the field of lectin microarray analysis was honored with a review article published in the journal Medical Research Archives.
Read more